
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics demonstrated a robust 17% year-over-year increase in the sale of nanochannel array flowcells, with sales reaching 7,233 in 2Q25 compared to 6,165 in 2Q24. Additionally, the company reported a combined revenue increase of 11% year-over-year for consumables, software, and other services in 2Q25, with notable growth of 16% in consumables and software revenue. Furthermore, Bionano increased its expectations for new optical genome mapping (OGM) installations in FY2025, projecting a range of 20-25, an improvement from the previous forecast of 15-20 installations.
Bears say
Bionano Genomics Inc faces a negative outlook primarily due to several operational and financial risks, including lower-than-expected market uptake of its products and reduced utilization of installed systems. Projections suggest a conservative EV/Revenue multiple of 1.2x based on a sales forecast of $6.50 per share, coupled with a net cash position of $3.28 per share, indicates potential challenges in achieving the projected price objective of approximately $11. Additionally, the company may grapple with difficulties in securing additional capital needed for operations, enhancing concerns regarding dilution risk for existing shareholders.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares